We are a global biopharma focused on severe diseases with operations in approximately 40 countries and global revenue of € 3.3 billion in 2014.
- We combine biology and chemistry to make major breakthroughs. By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families living with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.
- We partner with the leaders in the pharmaceutical industry. The complexities of severe diseases are beyond the expertise and resources of a single organisation. That is why we team up with partners - we play to our strengths and tap into organisations with greater or complementary strengths.